Coşkun 2009a.

Methods	A patient report of decreased appetite during immediate‐release methylphenidate treatment and maculopapular pruritic skin eruptions during OROS‐methylphenidate treatment
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 8 years old IQ: > 70 Sex: male Ethnicity: not stated Country: Turkey Comorbidity: EEG abnormalities Comedication: valproate, gabapentin Sociodemographics: not stated
Interventions	Immediate release methylphenidate 10‐20 mg/day for 2 months Treatment compliance: reported forgetting to take his medication sometimes OROS methylphenidate 18 mg/day for 1 week and 9 days Treament compliance: not stated
Outcomes	Non‐serious adverse events: Immediate release methylphenidate 10‐20 mg/day and valproate 400 mg/day: decreased appetite, no weight decrease OROS‐methylphenidate 18 mg/day and valproate 400 mg/day: maculopapular pruritic skin eruptions on the patient's neck, arms, and legs, 1 week after starting OROS methylphenidate treatment OROS‐methylphenidate free period for 5 weeks: skin lesions were almost healed Re‐administering of OROS‐methylphenidate 18 mg/day and gabapentin 300 mg/day: same skin eruptions with same severity, 9 days after starting OROS‐methylphenidate treatment again Discontinuation of medication: skin lesions abated within the next several weeks Restart of immediate release methylphenidate 10‐20 mg/day and gabapentin 300 mg/day, 4 months: no skin eruptions
Notes	Funding/vested interests: the authors report no conflicts of interest or ties Key conclusions of study authors: the patient reported AEs with OROS MPH on 2 different occasions, but no AE with IR MPH at 2 different trials. Emergence of AE with OROS MPH and disappearance with discontinuation at both trials may suggest enough causality between AE and OROS MPH treatment Comments from the review authors: unclear whether the authors believe methylphenidate caused the adverse events